Characteristics of patients with sudden (n = 4) or gradual onset (n = 19) of blastic transformation
Characteristics . | SBT . | Gradual BP . |
---|---|---|
No. patients | 4 | 19 |
Best CG response, no. patients | ||
CR | 4 | 0 |
PR | 0 | 2 |
Minor | 0 | 2 |
CHR only | 0 | 11 |
No CHR | 0 | 8 |
Best molecular response, no. patients | ||
Undetectable | 1 | 0* |
< 0.05 | 1 | 0 |
≥ 0.05 | 2 | 5 |
Median time to best CG response, mo (range) | 45 (3-6) | 9.3 (3-22) |
Median time from diagnosis to imatinib, mo (range) | 2.3 (0.1-34.9) | 73.2 (0.9-171.5) |
Time from start of imatinib to BP, mo (range) | 19.5 (12-25) | 7.3 (1.9-54.3) |
Morphology, no. patients | ||
Lymphoid | 2 | 8 |
Myeloid | 2 | 8 |
Unknown | 0 | 3 |
CE at start of imatinib, no. patients | 0 | 5 |
CE at BP, no. patients | 4 | 3† |
Prior therapy, no. patients | ||
IFN-α | 1 | 16 |
None | 3 | 3 |
Sokal risk group, no. patients low/intermediate/high | 3/1/0 | 10/4/5 |
No. dead | 0 | 15 |
Characteristics . | SBT . | Gradual BP . |
---|---|---|
No. patients | 4 | 19 |
Best CG response, no. patients | ||
CR | 4 | 0 |
PR | 0 | 2 |
Minor | 0 | 2 |
CHR only | 0 | 11 |
No CHR | 0 | 8 |
Best molecular response, no. patients | ||
Undetectable | 1 | 0* |
< 0.05 | 1 | 0 |
≥ 0.05 | 2 | 5 |
Median time to best CG response, mo (range) | 45 (3-6) | 9.3 (3-22) |
Median time from diagnosis to imatinib, mo (range) | 2.3 (0.1-34.9) | 73.2 (0.9-171.5) |
Time from start of imatinib to BP, mo (range) | 19.5 (12-25) | 7.3 (1.9-54.3) |
Morphology, no. patients | ||
Lymphoid | 2 | 8 |
Myeloid | 2 | 8 |
Unknown | 0 | 3 |
CE at start of imatinib, no. patients | 0 | 5 |
CE at BP, no. patients | 4 | 3† |
Prior therapy, no. patients | ||
IFN-α | 1 | 16 |
None | 3 | 3 |
Sokal risk group, no. patients low/intermediate/high | 3/1/0 | 10/4/5 |
No. dead | 0 | 15 |